Corporate Overview

Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. Compounds derived from Shattuck’s ARC platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead program, SL-172154 (SIRPα-Fc-CD40L), is designed to block the CD47 immune checkpoint and simultaneously activate the CD40 receptor, a member of the tumor necrosis factor superfamily, is being evaluated in multiple Phase 1 clinical trials.

Latest News

View all news

Featured Presentation

View All Presentations

Latest Events

View All Events